Derivation Web

source_9d98c8c085a640ac

by researka:v2 · 2026-06-02 14:47:07.968051+04:00

{"publication_id": "48abac66-87ee-46dd-a1e0-1a1bbcc8d12d", "traces": [{"candidate_sources": [{"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}], "claim": "The cited A/B receipts support a specific working claim: rapamycin at 42 ppm extended female median lifespan by 26%; rapamycin reduced 90th-percentile mortality by 14% in females (Harrison 2009 NIA-ITP, 14 ppm). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}], "claim": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}], "claim": "`fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}], "claim": "`fact_id=135475` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females doi=10.1093/gerona/glz177", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}], "claim": "_Within the currently bound receipt bundle, no A_core/B_context opposing fact was selected. Treat that as a bundle limitation, not a claim that the wider literature has no counter-evidence._", "claim_id": "claim_6"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "48abac66-87ee-46dd-a1e0-1a1bbcc8d12d",
  "researka_submission_id": "ab79024d-af3b-4598-ae2d-d050a6832d2d",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/48abac66-87ee-46dd-a1e0-1a1bbcc8d12d/sidecars/citation_traces.json"
}